Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Income from Continuing Operations (2016 - 2025)

Agios Pharmaceuticals' Income from Continuing Operations history spans 14 years, with the latest figure at 108039000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 11.93% year-over-year to 108039000.0; the TTM value through Dec 2025 reached 414557000.0, down 161.83%, while the annual FY2025 figure was 412781000.0, 161.27% down from the prior year.
  • Income from Continuing Operations reached 108039000.0 in Q4 2025 per AGIO's latest filing, down from 103433000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 947915000.0 in Q3 2024 to a low of 112543000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 41602050.0, with a median of 92004000.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: surged 1137.97% in 2024, then tumbled 110.91% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 98584000.0 in 2021, then increased by 5.98% to 92684000.0 in 2022, then fell by 3.51% to 95940000.0 in 2023, then fell by 0.61% to 96523000.0 in 2024, then fell by 11.93% to 108039000.0 in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Income from Continuing Operations are 108039000.0 (Q4 2025), 103433000.0 (Q3 2025), and 112543000.0 (Q2 2025).